The biological activities of oleocanthal from a molecular perspective

Nutrients

Volumn 10, Issue 5, 2018, Pages

  Pang, Kok Lun ^a   Chin, Kok Yong ^b  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Alzheimer s disease; Antioxidant; Cancer; Inflammation; Neuroprotection; Oleocanthal; Olive

Indexed keywords

AMYLOID BETA PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; OLEOCANTHAL; OLIVE OIL; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TAU PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ALDEHYDE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; NEUROPROTECTIVE AGENT; PHENOL DERIVATIVE;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTROCYTE; BIOLOGICAL ACTIVITY; BREAST CANCER; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CYTOTOXICITY; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECT; METABOLISM; NEOPLASM; NERVE CELL; TUMOR CELL LINE;

ALDEHYDES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASTROCYTES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; NEOPLASMS; NEURONS; NEUROPROTECTIVE AGENTS; OLIVE OIL; PHENOLS;

EID: 85046652637     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10050570     Document Type: Review

References (116)

1. Fogliano, V.; Sacchi, R. Oleocanthal in olive oil: Between myth and reality. Mol. Nutr. Food Res. 2006, 50, 5–6.
2. Vissers, M.N.; Zock, P.L.; Roodenburg, A.J.C.; Leenen, R.; Katan, M.B. Olive oil phenols are absorbed in humans. Hum. Nutr. Metab. 2001, 132, 409–417.
3. Pelucchi, C.; Bosetti, C.; Lipworth, L.; La Vecchia, C. Olive oil and cancer risk: An update of epidemiological findings through 2010. Curr. Pharm. Des. 2011, 17, 805–812.
4. Berry, E.M.; Arnoni, Y.; Aviram, M. The middle eastern and biblical origins of the Mediterranean diet. Public Health Nutr. 2011, 14, 2288–2295.
5. Scarmeas, N.; Luchsinger, J.A.; Schupf, N.; Brickman, A.M.; Cosentino, S.; Tang, M.X.; Stern, Y. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009, 302, 627–637.
6. Ruiz-Canela, M.; Martinez-Gonzalez, M.A. Olive oil in the primary prevention of cardiovascular disease. Maturitas 2011, 68, 245–250.
7. Chin, K.Y.; Pang, K.L. Therapeutic effects of olive and its derivatives on osteoarthritis: From bench to bedside. Nutrients 2017, 9, 1060.
8. Chin, K.-Y.; Ima-Nirwana, S. Olives and bone: A green osteoporosis prevention option. Int. J. Environ. Res. Public Health 2016, 13, 755.
9. Maalej, A.; Mahmoudi, A.; Bouallagui, Z.; Fki, I.; Marrekchi, R.; Sayadi, S. Olive phenolic compounds attenuate deltamethrin-induced liver and kidney toxicity through regulating oxidative stress, inflammation and apoptosis. Food Chem. Toxicol. 2017, 106, 455–465.
10. Takashima, T.; Sakata, Y.; Iwakiri, R.; Shiraishi, R.; Oda, Y.; Inoue, N.; Nakayama, A.; Toda, S.; Fujimoto, K. Feeding with olive oil attenuates inflammation in dextran sulfate sodium-induced colitis in rat. J. Nutr. Biochem. 2014, 25, 186–192.
11. Zheng, A.; Li, H.; Xu, J.; Cao, K.; Li, H.; Pu, W.; Yang, Z.; Peng, Y.; Long, J.; Liu, J.; et al. Hydroxytyrosol improves mitochondrial function and reduces oxidative stress in the brain of db/db mice: Role of AMP-activated protein kinase activation. Br. J. Nutr. 2015, 113, 1667–1676.
12. Camargo, A.; Rangel-Zuniga, O.A.; Haro, C.; Meza-Miranda, E.R.; Pena-Orihuela, P.; Meneses, M.E.; Marin, C.; Yubero-Serrano, E.M.; Perez-Martinez, P.; Delgado-Lista, J.; et al. Olive oil phenolic compounds decrease the postprandial inflammatory response by reducing postprandial plasma lipopolysaccharide levels. Food Chem. 2014, 162, 161–171.
13. Carnevale, R.; Pignatelli, P.; Nocella, C.; Loffredo, L.; Pastori, D.; Vicario, T.; Petruccioli, A.; Bartimoccia, S.; Violi, F. Extra virgin olive oil blunt post-prandial oxidative stress via NOX2 down-regulation. Atherosclerosis 2014, 235, 649–658.
14. Lauretti, E.; Iuliano, L.; Pratico, D. Extra-virgin olive oil ameliorates cognition and neuropathology of the 3xTg mice: Role of autophagy. Ann. Clin. Transl. Neurol. 2017, 4, 564–574.
15. Aguilera, C.M.; Mesa, M.D.; Ramirez-Tortosa, M.C.; Nestares, M.T.; Ros, E.; Gil, A. Sunflower oil does not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease. Clin. Nutr. 2004, 23, 673–681.
16. Medina, E.; de Castro, A.; Romero, C.; Brenes, M. Comparison of the concentrations of phenolic compounds in olive oils and other plant oils: Correlation with antimicrobial activity. J. Agric. Food Chem. 2006, 54, 4954–4961.
17. Tripoli, E.; Giammanco, M.; Tabacchi, G.; Majo, D.D.; Giammanco, S.; Guardia, M.L. The phenolic compounds of olive oil: Structure, biological activity and beneficial effects on human health. Nutr. Res. Rev. 2005, 18, 98–112.
18. Cicerale, S.; Conlan, X.A.; Barnett, N.W.; Sinclair, A.J.; Keast, R.S. Influence of heat on biological activity and concentration of oleocanthal—A natural anti-inflammatory agent in virgin olive oil. J. Agric. Food Chem. 2009, 57, 1326–1330.
19. Servili, M.; Esposto, S.; Fabiani, R.; Urbani, S.; Taticchi, A.; Mariucci, F.; Selvaggini, R.; Montedoro, G.F. Phenolic compounds in olive oil: Antioxidant, health and organoleptic activities according to their chemical structure. Inflammopharmacology 2009, 17, 76–84.
20. Montedoro, G.; Servili, M.; Baldioli, M.; Miniati, E. Simple and hydrolyzable phenolic compounds in virgin olive oil. 1. Their extraction, separation, and quantitative and semiquantitative evaluation by HPLC. J. Agric. Food Chem. 1992, 40, 1571–1576.
21. Montedoro, G.; Servili, M.; Baldioli, M.; Miniati, E. Simple and hydrolyzable phenolic compounds in virgin olive oil. 2. Initial characterization of the hydrolyzable fraction. J. Agric. Food Chem. 1992, 40, 1577–1580.
22. Montedoro, G.; Servili, M.; Baldioli, M.; Selvaggini, R.; Miniati, E.; Macchioni, A. Simple and hydrolyzable compounds in virgin olive oil. 3. Spectroscopic characterizations of the secoiridoid derivatives. J. Agric. Food Chem. 1993, 41, 2228–2234.
23. Smith, A.B.; Han, Q.; Breslin, P.A.S.; Beauchamp, G.K. Synthesis and assignment of absolute configuration of (—)-oleocanthal: A potent, naturally occurring non-steroidal anti-inflammatory and anti-oxidant agent derived from extra virgin olive oils. Org. Lett. 2005, 7, 5075–5078.
24. Smith, A.B.; 3rd; Sperry, J.B.; Han, Q. Syntheses of (—)-oleocanthal, a natural NSAID found in extra virgin olive oil, the (—)-deacetoxy-oleuropein aglycone, and related analogues. J. Org. Chem. 2007, 72, 6891–6900.
25. Valli, M.; Peviani, E.G.; Porta, A.; D’Alfonso, A.; Zanoni, G.; Vidari, G. A concise and efficient total synthesis of oleocanthal. Eur. J. Org. Chem. 2013, 2013, 4332–4336.
26. English, B.J.; Williams, R.M. Synthesis of (+/−)-oleocanthal via a tandem intramolecular Michael cyclization-HWE olefination. Tetrahedron Lett. 2009, 50, 2713.
27. Takahashi, K.; Morita, H.; Honda, T. Formal synthesis of (—)-oleocanthal by means of a SmI2-promoted intramolecular coupling of bromoalkyne with α, β-unsaturated ester. Tetrahedron Lett. 2012, 53, 3342–3345.
28. Beauchamp, G.K.; Keast, R.S.; Morel, D.; Lin, J.; Pika, J.; Han, Q.; Lee, C.H.; Smith, A.B.; Breslin, P.A. Phytochemistry: Ibuprofen-like activity in extra-virgin olive oil. Nature 2005, 437, 45–46.
29. Cicerale, S.; Breslin, P.A.; Beauchamp, G.K.; Keast, R.S. Sensory characterization of the irritant properties of oleocanthal, a natural anti-inflammatory agent in extra virgin olive oils. Chem. Senses 2009, 34, 333–339.
30. Abuznait, A.H.; Qosa, H.; Busnena, B.A.; El Sayed, K.A.; Kaddoumi, A. Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer’s disease: In vitro and in vivo studies. ACS Chem. Neurosci. 2013, 4, 973–982.
31. Des Gachons, C.P.; Uchida, K.; Bryant, B.; Shima, A.; Sperry, J.B.; Dankulich-Nagrudny, L.; Tominaga, M.; Smith, A.B.; 3rd; Beauchamp, G.K.; Breslin, P.A. Unusual pungency from extra-virgin olive oil is attributable to restricted spatial expression of the receptor of oleocanthal. J. Neurosci. 2011, 31, 999–1009.
32. Garcia-Villalba, R.; Carrasco-Pancorbo, A.; Nevedomskaya, E.; Mayboroda, O.A.; Deelder, A.M.; Segura-Carretero, A.; Fernandez-Gutierrez, A. Exploratory analysis of human urine by LC–ESI-TOF MS after high intake of olive oil: Understanding the metabolism of polyphenols. Anal. Bioanal. Chem. 2010, 398, 463–475.
33. Fini, L.; Hotchkiss, E.; Fogliano, V.; Graziani, G.; Romano, M.; De Vol, E.B.; Qin, H.; Selgrad, M.; Boland, C.R.; Ricciardiello, L. Chemopreventive properties of pinoresinol-rich olive oil involve a selective activation of the ATM-p53 cascade in colon cancer cell lines. Carcinogenesis 2008, 29, 139–146.
34. Casamenti, F.; Stefani, M. Olive polyphenols: New promising agents to combat aging-associated neurodegeneration. Expert Rev. Neurother. 2017, 17, 345–358.
35. Romero, C.; Medina, E.; Vargas, J.; Brenes, M.; De Castro, A. In vitro activity of olive oil polyphenols against Helicobacter pylori. J. Agric. Food Chem. 2007, 55, 680–686.
36. ChemSpider. Oleocanthal. Available online: http://www.chemspider.com/Chemical-Structure.9827154.html (accessed on 25 March 2018).
37. Fito, M.; de la Torre, R.; Farre-Albaladejo, M.; Khymenetz, O.; Marrugat, J.; Covas, M.-I. Bioavailability and antioxidant effects of olive oil phenolic compounds in humans: A review. Annali dell'Istituto Superiore Di Sanita 2007, 43, 375–381.
38. Corona, G.; Tzounis, X.; Dessi, M.A.; Deiana, M.; Debnam, E.S.; Visioli, F.; Spencer, J.P.E. The fate of olive oil polyphenols in the gastrointestinal tract: Implications of gastric and colonic microflora-dependent biotransformation. Free Radic. Res. 2006, 40, 647–658.
39. Andrewes, P.; Busch, J.L.; de Joode, T.; Groenewegen, A.; Alexandre, H. Sensory properties of virgin olive oil polyphenols: Identification of deacetoxy-ligstroside aglycon as a key contributor to pungency. J. Agric. Food Chem. 2003, 51, 1415–1420.
40. Bautista, D.M.; Pellegrino, M.; Tsunozaki, M. TRPA1: A gatekeeper for inflammation. Annu. Rev. Physiol. 2013, 75, 181–200.
41. Gouin, O.; L’Herondelle, K.; Lebonvallet, N.; Le Gall-Ianotto, C.; Sakka, M.; Buhe, V.; Plee-Gautier, E.; Carre, J.L.; Lefeuvre, L.; Misery, L.; et al. TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: Pro-inflammatory response induced by their activation and their sensitization. Protein Cell 2017, 8, 644–661.
42. Meseguer, V.; Alpizar, Y.A.; Luis, E.; Tajada, S.; Denlinger, B.; Fajardo, O.; Manenschijn, J.A.; Fernandez-Pena, C.; Talavera, A.; Kichko, T.; et al. TRPA1 channels mediate acute neurogenic inflammation and pain produced by bacterial endotoxins. Nat. Commun. 2014, 5, 3125.
43. Rosignoli, P.; Fuccelli, R.; Fabiani, R.; Servili, M.; Morozzi, G. Effect of olive oil phenols on the production of inflammatory mediators in freshly isolated human monocytes. J. Nutr. Biochem. 2013, 24, 1513–1519.
44. Vougogiannopoulou, K.; Lemus, C.; Halabalaki, M.; Pergola, C.; Werz, O.; Smith, A.B.; 3rd; Michel, S.; Skaltsounis, L.; Deguin, B. One-step semisynthesis of oleacein and the determination as a 5-lipoxygenase inhibitor. J. Nat. Prod. 2014, 77, 441–445.
45. Pergola, C.; Werz, O. 5-lipoxygenase inhibitors: A review of recent developments and patents. Expert Opin. Ther. Pat. 2010, 20, 355–375.
46. Murphy, R.C.; Gijon, M.A. Biosynthesis and metabolism of leukotrienes. Biochem. J. 2007, 405, 379–395.
47. Leone, S.; Ottani, A.; Bertolini, A. Dual acting anti-inflammatory drugs. Curr. Top. Med. Chem. 2007, 7, 265–275.
48. Burnett, B.P.; Levy, R.M. 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity. Adv. Ther. 2012, 29, 79–98.
49. Laidlaw, T.M.; Boyce, J.A. Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol. Allergy Clin. N. Am. 2013, 33, 195–210.
50. Scotece, M.; Gomez, R.; Conde, J.; Lopez, V.; Gomez-Reino, J.J.; Lago, F.; Smith, A.B.; 3rd; Gualillo, O. Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes. Life Sci. 2012, 91, 1229–1235.
51. Iacono, A.; Gomez, R.; Sperry, J.; Conde, J.; Bianco, G.; Meli, R.; Gomez-Reino, J.J.; Smith, A.B.; 3rd; Gualillo, O. Effect of oleocanthal and its derivatives on inflammatory response induced by lipopolysaccharide in a murine chondrocyte cell line. Arthritis Rheumatol. 2010, 62, 1675–1682.
52. Qosa, H.; Batarseh, Y.S.; Mohyeldin, M.M.; El Sayed, K.A.; Keller, J.N.; Kaddoumi, A. Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. ACS Chem. Neurosci. 2015, 6, 1849–1859.
53. Mete, M.; Aydemir, I.; Unsal, U.U.; Collu, F.; Vatandas, G.; Gurcu, B.; Duransoy, Y.K.; Taneli, F.; Tugrul, M.I.; Selcuki, M. Neuroprotective effects of oleocanthal, a compound in virgin olive oil, in a rat model of traumatic brain injury. Turk. Neurosurg. 2017.
54. Cicerale, S.; Lucas, L.J.; Keast, R.S.J. Antimicrobial, antioxidant and anti-inflammatory phenolic activities in extra virgin olive oil. Curr. Opin. Biotechnol. 2012, 23, 129–135.
55. Liu, Y.; McKeever, L.C.; Malik, N.S. Assessment of the antimicrobial activity of olive leaf extract against foodborne bacterial pathogens. Front. Microbiol. 2017, 8, 113.
56. Sudjana, A.N.; D’Orazio, C.; Ryan, V.; Rasool, N.; Ng, J.; Islam, N.; Riley, T.V.; Hammer, K.A. Antimicrobial activity of commercial olea europaea (olive) leaf extract. Int. J. Antimicrob. Agents 2009, 33, 461–463.
57. Medina, E.; de Castro, A.; Romero, C.; Ramirez, E.; Brenes, M. Effect of antimicrobial compounds from olive products on microorganisms related to health, food and agriculture. In Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education; Mendez-Vilas, A.; Ed.; Formatex Research Center: Badajoz, Spain, 2013; Volume 2, pp. 1087–1094.
58. Medina, E.; Brenes, M.; Garcia, A.; Romero, C.; De Castro, A. Bactericidal activity of glutaraldehyde-like compounds from olive products. J. Food Prot. 2009, 72, 2611–2614.
59. Tagliafierro, L.; Officioso, A.; Sorbo, S.; Basile, A.; Manna, C. The protective role of olive oil hydroxytyrosol against oxidative alterations induced by mercury in human erythrocytes. Food Chem. Toxicol. 2015, 82, 59–63.
60. Kalaiselvan, I.; Dicson, S.M.; Kasi, P.D. Olive oil and its phenolic constituent tyrosol attenuates dioxin-induced toxicity in peripheral blood mononuclear cells via an antioxidant-dependent mechanism. Nat. Prod. Res. 2015, 29, 2129–2132.
61. Galvano, F.; La Fauci, L.; Graziani, G.; Ferracane, R.; Masella, R.; Di Giacomo, C.; Scacco, A.; D’Archivio, M.; Vanella, L.; Galvano, G. Phenolic compounds and antioxidant activity of Italian extra virgin olive oil Monti Iblei. J. Med. Food 2007, 10, 650–656.
62. Majumder, M.; Dunn, L.; Liu, L.; Hasan, A.; Vincent, K.; Brackstone, M.; Hess, D.; Lala, P.K. COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Sci Rep. 2018, 8, 327.
63. Charalambous, M.P.; Lightfoot, T.; Speirs, V.; Horgan, K.; Gooderham, N.J. Expression of COX-2, NF-κB-p65, NF-κB-p50 and IKKα in malignant and adjacent normal human colorectal tissue. Br. J. Cancer 2009, 101, 106–115.
64. Fogli, S.; Arena, C.; Carpi, S.; Polini, B.; Bertini, S.; Digiacomo, M.; Gado, F.; Saba, A.; Saccomanni, G.; Breschi, M.C.; et al. Cytotoxic activity of oleocanthal isolated from virgin olive oil on human melanoma cells. Nutr. Cancer 2016, 68, 873–877.
65. Gu, Y.; Wang, J.; Peng, L. (—)-Oleocanthal exerts anti-melanoma activities and inhibits STAT3 signaling pathway. Oncol. Rep. 2017, 37, 483–491.
66. Elnagar, A.Y.; Sylvester, P.W.; El Sayed, K.A. (—)-Oleocanthal as a c-Met inhibitor for the control of metastatic breast and prostate cancers. Planta Med. 2011, 77, 1013–1019.
67. Busnena, B.A.; Foudah, A.I.; Melancon, T.; El Sayed, K.A. Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer. Bioorg. Med. Chem. 2013, 21, 2117–2127.
68. Mohyeldin, M.M.; Akl, M.R.; Ebrahim, H.Y.; Dragoi, A.M.; Dykes, S.; Cardelli, J.A.; El Sayed, K.A. The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. Oncotarget 2016, 7, 32247–32273.
69. Mohyeldin, M.M.; Busnena, B.A.; Akl, M.R.; Dragoi, A.M.; Cardelli, J.A.; El Sayed, K.A. Novel c-Met inhibitory olive secoiridoid semisynthetic analogs for the control of invasive breast cancer. Eur. J. Med. Chem. 2016, 118, 299–315.
70. Akl, M.R.; Ayoub, N.M.; Mohyeldin, M.M.; Busnena, B.A.; Foudah, A.I.; Liu, Y.Y.; Sayed, K.A. Olive phenolics as c-Met inhibitors: (—)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS ONE 2014, 9, e97622.
71. Khanfar, M.A.; Bardaweel, S.K.; Akl, M.R.; El Sayed, K.A. Olive oil-derived oleocanthal as potent inhibitor of mammalian target of rapamycin: Biological evaluation and molecular modeling studies. Phytother. Res. 2015, 29, 1776–1782.
72. Pei, T.; Meng, Q.; Han, J.; Sun, H.; Li, L.; Song, R.; Sun, B.; Pan, S.; Liang, D.; Liu, L. (—)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Oncotarget 2016, 7, 43475–43491.
73. Cusimano, A.; Balasus, D.; Azzolina, A.; Augello, G.; Emma, M.R.; Di Sano, C.; Gramignoli, R.; Strom, S.C.; McCubrey, J.A.; Montalto, G.; et al. Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation. Int. J. Oncol. 2017, 51, 533–544.
74. Khanal, P.; Oh, W.K.; Yun, H.J.; Namgoong, G.M.; Ahn, S.G.; Kwon, S.M.; Choi, H.K.; Choi, H.S. p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis. Carcinogenesis 2011, 32, 545–553.
75. Scotece, M.; Gomez, R.; Conde, J.; Lopez, V.; Gomez-Reino, J.J.; Lago, F.; Smith, A.B.; 3rd; Gualillo, O. Oleocanthal inhibits proliferation and MIP-1 expression in human multiple myeloma cells. Curr. Med. Chem. 2013, 20, 2467–2475.
76. Fabiani, R.; De Bartolomeo, A.; Rosignoli, P.; Servili, M.; Selvaggini, R.; Montedoro, G.F.; Di Saverio, C.; Morozzi, G. Virgin olive oil phenols inhibit proliferation of human promyelocytic leukemia cells (HL60) by inducing apoptosis and differentiation. Nutr. Dis. 2006, 136, 614–619.
77. LeGendre, O.; Breslin, P.A.; Foster, D.A. (—)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. Mol. Cell. Oncol. 2015, 2, e1006077.
78. Ayoub, N.M.; Siddique, A.B.; Ebrahim, H.Y.; Mohyeldin, M.M.; El Sayed, K.A. The olive oil phenolic (—)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment. Eur. J. Pharmacol. 2017, 810, 100–111.
79. Margarucci, L.; Monti, M.C.; Cassiano, C.; Mozzicafreddo, M.; Angeletti, M.; Riccio, R.; Tosco, A.; Casapullo, A. Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor. Chem. Commun. 2013, 49, 5844–5846.
80. Cassiano, C.; Casapullo, A.; Tosco, A.; Monti, M.C.; Riccio, R. In cell interactome of oleocanthal, an extra virgin olive oil bioactive component. Nat. Prod. Commun. 2015, 10, 1013–1016.
81. Keiler, A.M.; Zierau, O.; Bernhardt, R.; Scharnweber, D.; Lemonakis, N.; Termetzi, A.; Skaltsounis, L.; Vollmer, G.; Halabalaki, M. Impact of a functionalized olive oil extract on the uterus and the bone in a model of postmenopausal osteoporosis. Eur. J. Nutr. 2014, 53, 1073–1081.
82. Keiler, A.M.; Djiogue, S.; Ehrhardt, T.; Zierau, O.; Skaltsounis, L.; Halabalaki, M.; Vollmer, G. Oleocanthal modulates estradiol-induced gene expression involving estrogen receptor. Planta Med. 2015, 81, 1263–1269.
83. Abuznait, A.H.; Qosa, H.; O’Connell, N.D.; Akbarian-Tefaghi, J.; Sylvester, P.W.; El Sayed, K.A.; Kaddoumi, A. Induction of expression and functional activity of P-glycoprotein efflux transporter by bioactive plant natural products. Food Chem.Toxicol. 2011, 49, 2765–2772.
84. Wu, L.X.; Xu, J.H.; Zhang, K.Z.; Lin, Q.; Huang, X.W.; Wen, C.X.; Chen, Y.Z. Disruption of the Bcr-Abl/Hsp90 protein complex: A possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin. Leukemia 2008, 22, 1402–1409.
85. Knoblauch, R.; Garabedian, M.J. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol. Cell. Biol. 1999, 19, 3748–3759.
86. Fliss, A.E.; Benzeno, S.; Rao, J.; Caplan, A.J. Control of estrogen receptor ligand binding by Hsp90. J. Steroid Biochem. Mol. Biol. 2000, 72, 223–230.
87. Schopf, F.H.; Biebl, M.M.; Buchner, J. The Hsp90 chaperone machinery. Nat. Rev. Mol. Cell. Biol. 2017, 18, 345–360.
88. Wang, K.; Ma, Q.; Ren, Y.; He, J.; Zhang, Y.; Zhang, Y.; Chen, W. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/β-catenin signaling in HER2 overexpressing human breast cancer cells. Oncol. Rep. 2007, 17, 89–96.
89. McCleese, J.K.; Bear, M.D.; Fossey, S.L.; Mihalek, R.M.; Foley, K.P.; Ying, W.; Barsoum, J.; London, C.A. The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer 2009, 125, 2792–2801.
90. Webb, C.P.; Hose, C.D.; Koochekpour, S.; Jeffers, M.; Oskarsson, M.; Sausville, E.; Monks, A.; Woude, G.F.V. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 2000, 60, 342–349.
91. Wang, S.; Pashtan, I.; Tsutsumi, S.; Xu, W.; Neckers, L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 2009, 8, 2050–2056.
92. Bocchini, C.E.; Kasembeli, M.M.; Roh, S.H.; Tweardy, D.J. Contribution of chaperones to STAT pathway signaling. JAKSTAT 2014, 3, e970459.
93. Subik, K.; Lee, J.-F.; Baxter, L.; Strzepek, T.; Costello, D.; Crowley, P.; Xing, L.; Hung, M.-C.; Bonfiglio, T.; Hicks, D.G.; et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer Basic Clin. Res. 2010, 4, 35–41.
94. De Mattos-Arruda, L.; Cortes, J. Breast cancer and Hsp90 inhibitors: Is there a role beyond the HER2-positive subtype? Breast 2012, 21, 604–607.
95. Zhang, Y.J.; Dai, Q.; Sun, D.F.; Xiong, H.; Tian, X.Q.; Gao, F.H.; Xu, M.H.; Chen, G.Q.; Han, Z.G.; Fang, J.Y. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann. Surg. Oncol. 2009, 16, 2617–2628.
96. Zhang, Y.J.; Tian, X.Q.; Sun, D.F.; Zhao, S.L.; Xiong, H.; Fang, J.Y. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer Investig. 2009, 27, 273–285.
97. Zhang, Y.; Zheng, X.F. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 2012, 11, 594–603.
98. van Assema, D.M.; Lubberink, M.; Bauer, M.; van der Flier, W.M.; Schuit, R.C.; Windhorst, A.D.; Comans, E.F.; Hoetjes, N.J.; Tolboom, N.; Langer, O.; et al. Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 2012, 135, 181–189.
99. Miceli, T.S.; Colson, K.; Faiman, B.M.; Miller, K.; Tariman, J.D.; International Myeloma Foundation Nurse Leadership, B. Maintaining bone health in patients with multiple myeloma: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clin. J. Oncol. Nurs. 2011, 15, 9–23.
100. Terpos, E.; Politou, M.; Viniou, N.; Rahemtulla, A. Significance of macrophage inflammatory protein-1 alpha (MIP-1) in multiple myeloma. Leuk Lymphoma 2005, 46, 1699–1707.
101. Tsubaki, M.; Kato, C.; Manno, M.; Ogaki, M.; Satou, T.; Itoh, T.; Kusunoki, T.; Tanimori, Y.; Fujiwara, K.; Matsuoka, H.; et al. Macrophage inflammatory protein-1α (MIP-1α) enhances a receptor activator of nuclear factor kB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol. Cell. Biochem. 2007, 304, 53–60.
102. Choi, S.J.; Cruz, J.C.; Craig, F.; Chung, H.; Devlin, R.D.; Roodman, G.D.; Alsina, M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000, 96, 671–675.
103. Li, W.; Sperry, J.B.; Crowe, A.; Trojanowski, J.Q.; Smith, A.B.; 3rd; Lee, V.M. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J. Neurochem. 2009, 110, 1339–1351.
104. Monti, M.C.; Margarucci, L.; Tosco, A.; Riccio, R.; Casapullo, A. New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component. Food Funct. 2011, 2, 423–428.
105. Monti, M.C.; Margarucci, L.; Riccio, R.; Casapullo, A. Modulation of tau protein fibrillization by oleocanthal. J. Nat. Prod. 2012, 75, 1584–1588.
106. Cirrito, J.R.; Deane, R.; Fagan, A.M.; Spinner, M.L.; Parsadanian, M.; Finn, M.B.; Jiang, H.; Prior, J.L.; Sagare, A.; Bales, K.R.; et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-βdeposition in an Alzheimer disease mouse model. J. Clin. Investig. 2005, 115, 3285–3290.
107. Yamada, K.; Hashimoto, T.; Yabuki, C.; Nagae, Y.; Tachikawa, M.; Strickland, D.K.; Liu, Q.; Bu, G.; Basak, J.M.; Holtzman, D.M.; et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid bpeptides in an in vitro model of the blood-brain barrier cells. J. Biol. Chem. 2008, 283, 34554–34562.
108. Pitt, J.; Roth, W.; Lacor, P.; Smith, A.B.; Blankenship, M.; Velasco, P.; De Felice, F.; Breslin, P.; Klein, W.L. Alzheimer's-associated a β oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol. Appl. Pharmacol. 2009, 240, 189–197.
109. Batarseh, Y.S.; Mohamed, L.A.; Al Rihani, S.B.; Mousa, Y.M.; Siddique, A.B.; El Sayed, K.A.; Kaddoumi, A. Oleocanthal ameliorates amyloid-βoligomers' toxicity on astrocytes and neuronal cells: In vitro studies. Neuroscience 2017, 352, 204–215.
110. Selkoe, D.J. Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192, 106–113.
111. Katsouri, L.; Parr, C.; Bogdanovic, N.; Willem, M.; Sastre, M. PPAR co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPAR -dependent mechanism. J. Alzheimers Dis. 2011, 25, 151–162.
112. Heneka, M.T.; Reyes-Irisarri, E.; Hüll, M.; Kummer, M.P. Impact and therapeutic potential of PPARs in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9, 643–650.
113. Sastre, M.; Dewachter, I.; Landreth, G.E.; Willson, T.M.; Klockgether, T.; van Leuven, F.; Heneka, M.T. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor- agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J. Neurosci. 2003, 23, 9796–9804.
114. Toutain, P.-L.; Ferran, A.; Bousquet-Mélou, A. Species differences in pharmacokinetics and pharmacodynamics. In Comparative and Veterinary Pharmacology; Cunningham, F.; Elliott, J.; Lees, P.; Eds.; Springer: Berlin/Heidelberg, Germany, 2010; pp. 19–48.
115. Musther, H.; Olivares-Morales, A.; Hatley, O.J.; Liu, B.; Rostami Hodjegan, A. Animal versus human oral drug bioavailability: Do they correlate? Eur. J. Pharm. Sci. 2014, 57, 280–291.
116. De la Torre, R. Bioavailability of olive oil phenolic compounds in humans. Inflammopharmacology 2008, 16, 245–247.